The Indian Practitioner

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

A Review of the Aetiology, Characterisation, Diagnosis and Treatment of Alzheimer's Disease


     

   Subscribe/Renew Journal


Not too long ago, Alzheimer's (AD) disease was looked upon as a problem affecting only rich countries and affluent societies and therefore not of much relevance to a country like India. Not so any more. In India, 3.7 million people are said to be affected by this condition as of 2016 with the figure doubling by the year 2030. Compare this with the figures for the United States where AD affects 5.4 million people as of 2017 with the number rising to 13.8 million by the year 2050. Clearly we in India cannot afford to be complacent on this front, especially because more and more senior citizens are now living up to ripe old age putting enormous pressure on our limited healthcare resources.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Alzheimer disease. Shaheen E Lakhan, Medscape Jul 26, 2017

  • Alzheimer’s Association. 2016 Alzheimer’s disease facts and figures. Alzheimers Dement. 2016 Apr. 12 (4):459-509.

  • Xu W, Tan L, Wang HF, Jiang T, Tan MS, Tan L, et al. Meta-analysis of modifiable risk factors for Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2015 Dec. 86 (12):1299-306

  • Anderson, P. Early-Life Depression Boosts Alzheimer’s Risk. Medscape Medical News. July 24, 2017

  • Chiang GC, Insel PS, Tosun D, et al. Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects. Neurology. 2010 Nov 30. 75(22):1976-81

  • Rodrigue KM, Rieck JR, Kennedy KM, Devous MD, Diaz-Arrastia R, Park DC. Risk Factors for ßAmyloid Deposition in Healthy Aging: Vascular and Genetic Effects. JAMA Neurol. 2013 Mar 18. 1-7.

  • Schrijvers JCM, Witteman EJG, Sijbrands, et al. Insulin metabolism and the risk of Alzheimer disease: The Rotterdam Study. Neurology. 2010;75:19821987.

  • Saczynski JS, Beiser A, Seshadri S, Auerbach S, Wolf PA, Au R. Depressive symptoms and risk of dementia: the Framingham Heart Study. Neurology. 2010 Jul 6. 75(1):35-41

  • Lowry F. Late-life depression linked to increased risk for dementia. Medscape Medical News. May 7, 2013

  • Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF 3rd. Late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of communitybased cohort studies. Br J Psychiatry. 2013 May. 202:329-35

  • Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N Engl J Med. 2009 May 28. 360(22):23029

  • McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011 May. 7(3):263-9. .

  • American Psychiatric Association. Neurocognitive Disorders. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American Psychiatric Association; 2013. 611-614.

  • McMillan CT, Avants B, Irwin DJ, Toledo JB, et al. Can MRI screen for CSF biomarkers in neurodegenerative disease?. Neurology. 2012 Dec 26

  • Brooks M. Functional Brain Imaging May Spot Alzheimer’s Early. Medscape Medical News. Aug 21 2013

  • Greig SL. Memantine ER/Donepezil: A Review in Alzheimer’s Disease. CNS Drugs. 2015 Nov. 29 (11):963-70

  • Small GW. Treating dementia and agitation. JAMA. 2014 Feb 19. 311(7):677-8

  • Wang YY, Zheng W, Ng CH, Ungvari GS, Wei W, Xiang YT. Meta-analysis of randomized, doubleblind, placebo-controlled trials of melatonin in Alzheimer’s disease. Int J Geriatr Psychiatry. 2016 Sep 19.

  • Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014 Jan 1. 311(1):33-44.

  • Yaffe K, Boustani M. Benzodiazepines and risk of Alzheimer’s disease. BMJ. 2014 Sep 9. 349:g5312.


Abstract Views: 286

PDF Views: 2




  • A Review of the Aetiology, Characterisation, Diagnosis and Treatment of Alzheimer's Disease

Abstract Views: 286  |  PDF Views: 2

Authors

Abstract


Not too long ago, Alzheimer's (AD) disease was looked upon as a problem affecting only rich countries and affluent societies and therefore not of much relevance to a country like India. Not so any more. In India, 3.7 million people are said to be affected by this condition as of 2016 with the figure doubling by the year 2030. Compare this with the figures for the United States where AD affects 5.4 million people as of 2017 with the number rising to 13.8 million by the year 2050. Clearly we in India cannot afford to be complacent on this front, especially because more and more senior citizens are now living up to ripe old age putting enormous pressure on our limited healthcare resources.

References